DBV Technologies S.A. to Release Full Year 2023 Financial Results and Business Update on March 7, 2024
Montrouge, France – DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a leading clinical-stage biopharmaceutical company specializing in treatments for food allergies, has announced that it will be hosting a conference call and live audio webcast on Thursday, March 7th at 5:00 p.m. ET to discuss its full year 2023 financial results and provide a business update.
Interested participants can access the call by dialing the following numbers:
– United States: 1-844-481-2866
– International: 1-412-317-1859
A live webcast of the call will also be available on the Company’s website under the “Events” section in the Investors’ area. A replay of the presentation will be accessible on DBV’s website following the event.
DBV Technologies is known for developing Viaskin™, a proprietary investigational Technology platform with vast potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy (EPIT™) and offers a new method of delivering biologically active compounds to the immune system through intact skin. DBV Technologies’ dedication to safely transforming the care of food allergic patients reflects its ongoing clinical trials of Viaskin Peanut. The company’s global headquarters are based in Montrouge, France, with North American operations in Basking Ridge, NJ. DBV Technologies’ shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and its ADSs are listed on the Nasdaq Global Select Market (Ticker: DBVT).
For investor inquiries, please contact Katie Matthews at katie.matthews@dbv-technologies.com. For media inquiries, please reach out to Aurora Krause at aurora.krause-ext@dbv-technologies.com.
Viaskin and EPIT are trademarks of DBV Technologies.
Attachment:
A visual representation of DBV Technologies S.A.
In summary, DBV Technologies S.A. continues to make strides in the field of immunotherapy for food allergies, with a strong focus on innovation and patient care. Stay tuned for their upcoming financial results and business updates on March 7, 2024.
Read More Business News
